Microelectronic array system for molecular diagnostic genotyping: Nanogen NanoChip® 400 and Molecular Biology Workstation

Dianne Keen-Kim, Wayne W. Grody, Carolyn (Sue) Richards

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Hundreds of gene mutations responsible for Mendelian disorders are currently tested in the clinical laboratory for pre- and postnatal diagnosis, carrier screening and presymptomatic testing. Since human genetic research is currently focused on determining the etiology of complex diseases, including heart disease, diabetes and neuropsychiatric traits, laboratorians will genotype increasing numbers of clinically relevant loci in the future. This will require accurate, high-throughput and cost-effective genotyping platforms, such as the DNA microarray. The Nanogen NanoChip® platforms employ hybridization-based technology, using fluorescent detection and electronic control of the target or probe, to obtain clear genotype signal relative to background, and increased flexibility relative to similar chip-based single nucleotide polymorphism genotyping platforms. The scope of this review is intended to describe the operating principle, chips and instrumentation, analyte-specific reagents, published assay protocols, assay development, and clinical use of the NanoChip platforms. It is beyond the scope of this review to describe the use of NanoChip platforms in basic research, and to compare it against all available clinical single nucleotide polymorphism genotyping applications and platforms.

Original languageEnglish (US)
Pages (from-to)287-294
Number of pages8
JournalExpert Review of Molecular Diagnostics
Volume6
Issue number3
DOIs
StatePublished - 2006

Fingerprint

Molecular Pathology
Single Nucleotide Polymorphism
Molecular Biology
Genotype
Genetic Research
Medical Genetics
Oligonucleotide Array Sequence Analysis
Prenatal Diagnosis
Heart Diseases
Technology
Costs and Cost Analysis
Mutation
Research
Genes

Keywords

  • Analyte-specific reagent
  • Microarray
  • Molecular biology workstation
  • NanoChip®
  • NanoChip® 400
  • SNP genotyping

ASJC Scopus subject areas

  • Genetics

Cite this

Microelectronic array system for molecular diagnostic genotyping : Nanogen NanoChip® 400 and Molecular Biology Workstation. / Keen-Kim, Dianne; Grody, Wayne W.; Richards, Carolyn (Sue).

In: Expert Review of Molecular Diagnostics, Vol. 6, No. 3, 2006, p. 287-294.

Research output: Contribution to journalArticle

@article{99f1848e038243c083d99063f38d53d5,
title = "Microelectronic array system for molecular diagnostic genotyping: Nanogen NanoChip{\circledR} 400 and Molecular Biology Workstation",
abstract = "Hundreds of gene mutations responsible for Mendelian disorders are currently tested in the clinical laboratory for pre- and postnatal diagnosis, carrier screening and presymptomatic testing. Since human genetic research is currently focused on determining the etiology of complex diseases, including heart disease, diabetes and neuropsychiatric traits, laboratorians will genotype increasing numbers of clinically relevant loci in the future. This will require accurate, high-throughput and cost-effective genotyping platforms, such as the DNA microarray. The Nanogen NanoChip{\circledR} platforms employ hybridization-based technology, using fluorescent detection and electronic control of the target or probe, to obtain clear genotype signal relative to background, and increased flexibility relative to similar chip-based single nucleotide polymorphism genotyping platforms. The scope of this review is intended to describe the operating principle, chips and instrumentation, analyte-specific reagents, published assay protocols, assay development, and clinical use of the NanoChip platforms. It is beyond the scope of this review to describe the use of NanoChip platforms in basic research, and to compare it against all available clinical single nucleotide polymorphism genotyping applications and platforms.",
keywords = "Analyte-specific reagent, Microarray, Molecular biology workstation, NanoChip{\circledR}, NanoChip{\circledR} 400, SNP genotyping",
author = "Dianne Keen-Kim and Grody, {Wayne W.} and Richards, {Carolyn (Sue)}",
year = "2006",
doi = "10.1586/14737159.6.3.287",
language = "English (US)",
volume = "6",
pages = "287--294",
journal = "Expert Review of Molecular Diagnostics",
issn = "1473-7159",
publisher = "Expert Reviews Ltd.",
number = "3",

}

TY - JOUR

T1 - Microelectronic array system for molecular diagnostic genotyping

T2 - Nanogen NanoChip® 400 and Molecular Biology Workstation

AU - Keen-Kim, Dianne

AU - Grody, Wayne W.

AU - Richards, Carolyn (Sue)

PY - 2006

Y1 - 2006

N2 - Hundreds of gene mutations responsible for Mendelian disorders are currently tested in the clinical laboratory for pre- and postnatal diagnosis, carrier screening and presymptomatic testing. Since human genetic research is currently focused on determining the etiology of complex diseases, including heart disease, diabetes and neuropsychiatric traits, laboratorians will genotype increasing numbers of clinically relevant loci in the future. This will require accurate, high-throughput and cost-effective genotyping platforms, such as the DNA microarray. The Nanogen NanoChip® platforms employ hybridization-based technology, using fluorescent detection and electronic control of the target or probe, to obtain clear genotype signal relative to background, and increased flexibility relative to similar chip-based single nucleotide polymorphism genotyping platforms. The scope of this review is intended to describe the operating principle, chips and instrumentation, analyte-specific reagents, published assay protocols, assay development, and clinical use of the NanoChip platforms. It is beyond the scope of this review to describe the use of NanoChip platforms in basic research, and to compare it against all available clinical single nucleotide polymorphism genotyping applications and platforms.

AB - Hundreds of gene mutations responsible for Mendelian disorders are currently tested in the clinical laboratory for pre- and postnatal diagnosis, carrier screening and presymptomatic testing. Since human genetic research is currently focused on determining the etiology of complex diseases, including heart disease, diabetes and neuropsychiatric traits, laboratorians will genotype increasing numbers of clinically relevant loci in the future. This will require accurate, high-throughput and cost-effective genotyping platforms, such as the DNA microarray. The Nanogen NanoChip® platforms employ hybridization-based technology, using fluorescent detection and electronic control of the target or probe, to obtain clear genotype signal relative to background, and increased flexibility relative to similar chip-based single nucleotide polymorphism genotyping platforms. The scope of this review is intended to describe the operating principle, chips and instrumentation, analyte-specific reagents, published assay protocols, assay development, and clinical use of the NanoChip platforms. It is beyond the scope of this review to describe the use of NanoChip platforms in basic research, and to compare it against all available clinical single nucleotide polymorphism genotyping applications and platforms.

KW - Analyte-specific reagent

KW - Microarray

KW - Molecular biology workstation

KW - NanoChip®

KW - NanoChip® 400

KW - SNP genotyping

UR - http://www.scopus.com/inward/record.url?scp=33745962246&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745962246&partnerID=8YFLogxK

U2 - 10.1586/14737159.6.3.287

DO - 10.1586/14737159.6.3.287

M3 - Article

C2 - 16706733

AN - SCOPUS:33745962246

VL - 6

SP - 287

EP - 294

JO - Expert Review of Molecular Diagnostics

JF - Expert Review of Molecular Diagnostics

SN - 1473-7159

IS - 3

ER -